Meet the editorial board

CTEPH.com is developed by Bayer HealthCare. Bayer is committed to advancing CTEPH best practices and to contributing to enhanced understanding of CTEPH throughout the healthcare community. Toward that end, CTEPH.com has enlisted an editorial board of eminent experts in CTEPH.

The editorial board members play several roles on CTEPH.com:

To guide the overall direction of CTEPH.com
To suggest topics, cases, and features for development on CTEPH.com
To review materials to be included on the site for medical accuracy and clinical relevance
To contribute their own work to the collection of materials contained on the site
To narrate educational videos explaining various aspects of CTEPH

Under the expert guidance of the editorial board, CTEPH.com will bring you up-to-date, clinically relevant information about CTEPH, with updates throughout the year. We hope you will visit CTEPH.com again soon to see what’s new.

Richard N. Channick, MD*

Richard N. Channick, MD, is Professor of Medicine at David Geffen School of Medicine at UCLA and Co-Director of the Pulmonary Vascular Disease Program at UCLA Medical Center.

Dr. Channick received his medical degree from Temple University Medical School, where he was elected to the Alpha Omega Alpha Medical Honor Society. He did his residency and was Chief Resident at the University of Massachusetts Medical Center. He did a pulmonary and critical care fellowship at the University of California, San Diego Medical Center. Dr. Channick was at UCSD for 20 years, helping build the pulmonary vascular program there.

From 2009-2018, Dr. Channick was at Massachusetts General Hospital, Harvard Medical School where he built a large Pulmonary Vascular Program. He has been at UCLA since September 2018, directing the UCLA Acute and Chronic Thromboembolic Disease Program.

Dr. Channick has published over 200 original articles, chapters, and reviews focused on all aspects of pulmonary hypertension and pulmonary embolism. He serves on many national and international leadership committees including the American Thoracic Society Pulmonary Circulation Program Committee and the American College of Chest Physicians Pulmonary Vascular Disease Network steering committee, past Chair of the Scientific Leadership Committee, and President Elect of the National Pulmonary Embolism Response Team (PERT) Consortium.

Dr. Channick has served on the steering committees for several pivotal clinical trials in pulmonary hypertension and lectures nationally and internationally.

Paul R. Forfia, MD*

Paul R. Forfia, MD, began his faculty career in 2006 at the Hospital of the University of Pennsylvania, Philadelphia, serving as the Director of the Pulmonary Hypertension Program. In 2013, Dr. Forfia joined the faculty at Temple University Hospital in Philadelphia, where he is a Professor of Medicine, and Co-Director of the Pulmonary Hypertension, Right Heart Failure, and CTEPH Program.

Dr. Forfia earned his master’s degree in Physiology and medical degree from New York Medical College in Valhalla, New York. He completed his residency in Internal Medicine and fellowships in Cardiovascular Disease and Heart Failure/Transplantation at Johns Hopkins Hospital, Baltimore, Maryland. Dr. Forfia also received additional training in pulmonary hypertension at Johns Hopkins.

Dr. Forfia’s clinical interests include pulmonary hypertension, CTEPH, right heart dysfunction, and the investigation of dyspnea. His research focuses on the noninvasive assessment of right heart and pulmonary vascular function, exercise physiology, and the physiologic phenotyping of non-PAH forms of pulmonary hypertension. He serves as an editor to numerous high-impact journals and has published more than 90 manuscripts and book chapters, mostly in the areas of PH and right heart function.

Gustavo A. Heresi-Davila, MD, MS*

Gustavo A. Heresi-Davila, MD, MS, is the Director of the Pulmonary Vascular and CTEPH Program in the Respiratory Institute at Cleveland Clinic, as well as a Co-Director of the Cleveland Clinic Pulmonary Embolism Response Team (PERT). He is board certified in Pulmonary Disease and Critical Care Medicine.

After receiving his medical degree from the University of San Agustin Faculty of Medicine in Arequipa, Peru, Dr. Heresi completed his internship and residency in Internal Medicine at the University of Miami-Jackson Memorial Medical Center in Miami, Florida. He completed his fellowship in Pulmonary and Critical Care Medicine at The Cleveland Clinic. He received a master's degree in Clinical Research from Case Western Reserve University. He is Assistant Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Dr. Heresi's clinical interests are in pulmonary hypertension, acute pulmonary embolism, and chronic thromboembolic pulmonary hypertension (CTEPH). Dr. Heresi has focused his research efforts on his specialty interests, including risk prediction, non-invasive biomarkers and metabolic dysregulation in pulmonary arterial hypertension, management of acute pulmonary embolism, and diagnosis and treatment of CTEPH. He is an NIH-funded investigator. He is the author of more than 70 peer-reviewed articles and is an Editorial Board member for CHEST.

Dr. Heresi has been the recipient of many awards including The Medical Student Inpatient Teaching Award, University of Miami School of Medicine 2004; Distinguished Medical Resident Award, Department of Medicine, University of Miami 2005; Gilead Sciences Research Scholars Program Award in Pulmonary Arterial Hypertension 2009; Young Investigator Award, American College of Chest Physicians 2012; and Teacher of the Year Award, Cleveland Clinic Pulmonary and Critical Care Fellowship 2013-2014.

Nick H. Kim, MD*

Nick H. Kim, MD, is Professor of Medicine in the Division of Pulmonary, Critical Care and Sleep Medicine at the University of California, San Diego (UCSD). He is Section Chief of Pulmonary Vascular Medicine and PTE Medical Director.

Dr. Kim graduated from Harvard University, Cambridge, Massachusetts, and received his medical degree in 1994 from the University of Chicago Pritzker School of Medicine, Chicago, Illinois. He completed his Internal Medicine internship and residency at the University of Chicago and a year of anesthesiology training at UCSF. After completing fellowship training in Pulmonary and Critical Care Medicine at UCSD in 2001, he joined the faculty specializing in pulmonary vascular medicine.

Dr. Kim’s clinical and research interests are in pulmonary hypertension and chronic thromboembolic disease. He serves on the steering committee for numerous pulmonary hypertension clinical trials and registries, has published in numerous peer-reviewed journals, and has lectured internationally on the subject of pulmonary hypertension.

Michael M. Madani, MD, FACS*

Michael M. Madani, MD, FACS, is Professor of Surgery, Division Chief of Cardiovascular and Thoracic Surgery, and Director of the Sulpizio Cardiovascular Center–Surgery at the University of California, San Diego (USCD), La Jolla. He is also the surgical director of the Pulmonary Endarterectomy program at UCSD.

Dr. Madani received his medical degree from University of Toronto, Canada, and completed his residency in general surgery at the Berkshire Medical Center, University of Massachusetts Medical School, and his advanced fellowship training in cardiovascular and thoracic surgery at UCSD. He is certified by the American Board of Surgery and the American Board of Thoracic Surgery.

Dr. Madani’s research interests at UCSD are focused on the surgical treatment for chronic thromboembolic pulmonary hypertension, as well as outcomes of pulmonary endarterectomy for treating extreme thromboembolic pulmonary hypertension. He was an investigator in an ongoing national multicenter study devoted to establishing the United States CTEPH Registry, which is creating a national database of all patients with CTEPH. Dr. Mandani is also an author of numerous publications on the surgical treatment of CTEPH and cardiac disease in peer-reviewed journals such as Journal of the American College of Cardiology, the American Journal of Surgery, the Journal of Thoracic and Cardiovascular Surgery, and the Annals of Thoracic Surgery.

Ivan M. Robbins, MD

Ivan M. Robbins, MD, is Professor of Medicine and Director, Adult Pulmonary Hypertension Center, in the division of Allergy, Pulmonary, and Critical Care Medicine at Vanderbilt University Medical Center, Nashville, Tennessee.

Beginning his education with an undergraduate degree from Brown University, Providence, Rhode Island, in 1981, Dr. Robbins went on to earn his medical degree from Case Western Reserve School of Medicine, Cleveland, Ohio, in 1991. He trained in Internal Medicine at Metrohealth Medical Center in Cleveland from 1991 to 1994 and completed a Pulmonary and Critical Care Fellowship at Vanderbilt University, Nashville, Tennessee, between 1994 to 1997.

Dr. Robbins is an expert in pulmonary vascular disease and is board certified in Pulmonary Medicine. He directs the adult Pulmonary Vascular Center at Vanderbilt University. His research has focused on new treatments for pulmonary arterial hypertension. He regularly participates in clinical research and clinical trials, and is a peer reviewer for a host of specialty respiratory and cardiology journals, as well as those in general medicine.

Todd Bull, MD*

Todd Bull, MD, is the Director of the Centers for Lungs and Breathing, Medical Director of the Pulmonary Vascular Disease Center, and Professor of Medicine–Pulmonary Sciences & Critical Care at University of Colorado Hospital.

Dr. Bull received his medical degree from University of Colorado School of Medicine in 1994. He completed his residency of internal medicine at UT Southwestern Medical Center, Dallas, Texas, and a fellowship in pulmonary/critical care at University of Colorado Health Sciences Center.

Dr. Bull’s laboratories research interests revolve around the mechanisms of development, diagnosis, and treatment of pulmonary hypertension. A major focus of Dr. Bull’s work is the identification and assessment of novel biomarkers for the assessment and risk stratification of pulmonary vascular disease.

Vallerie V. McLaughlin, MD*

Vallerie V. McLaughlin, MD, is the Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine, and Director of the Pulmonary Hypertension Program at the University of Michigan. She is Associate Chief Clinical Officer for Cardiovascular Services of the University of Michigan Medical Group and Associate Chief of the Division of Cardiovascular Medicine.

She received her medical degree from Northwestern University Feinberg School of Medicine in Chicago, Illinois, and completed her internal medicine residency at University of Michigan Hospitals and cardiology fellowship at Northwestern University.

Dr. McLaughlin is a Fellow of the American College of Cardiology, American College of Chest Physicians, and American Heart Association (AHA). She has been the Principal Investigator of several major clinical trials of drug therapies for pulmonary arterial hypertension and has published numerous papers in this field. Dr. McLaughlin is an editorial board member of Chest, a Guest Editor for the Journal of the American College of Cardiology, and past Editor-in-Chief of Advances in Pulmonary Hypertension. She is a past Chair of the Scientific Leadership Committee and immediate past Chair of the Board of Trustees of the Pulmonary Hypertension Association, has chaired the American College of Cardiology Foundation/AHA Clinical Expert Consensus Document Committee for Pulmonary Arterial Hypertension, and has served on the Organizing Committee of the World Symposium on Pulmonary Hypertension.

Oksana Shlobin, MD*

Oksana Shlobin, MD, is an Advanced Lung Disease and Transplant Pulmonologist at Inova Heart and Vascular Institute, Virginia.

Dr. Shlobin serves as Medical Director, Pulmonary Vascular Disease Program and Director of Education, Advanced Lung Disease and Transplant Program at Inova Heart and Vascular Institute, Falls Church, Virginia.

Dr. Shlobin received her BS and MD from Georgetown University, and completed her residency in Internal Medicine at Harvard Medical School. She completed her fellowship in Pulmonary Critical Care at Johns Hopkins University.

Fernando Torres, MD*

Fernando Torres, MD, is a Professor of Medicine at UT Southwestern Medical Center and Head of the Lung Transplant and Pulmonary Hypertension Programs at William P. Clements Jr. University Hospital.

His clinical interests include pulmonary hypertension, lung transplantation, lung volume reduction surgery for emphysema, viral infections in immunosuppressed patients, and clinical outcomes research in lung transplantation and pulmonary hypertension.

Dr. Torres has served as principal investigator or coinvestigator in many clinical trials, including multicenter clinical trials to improve the survival of lung transplant and pulmonary hypertension patients. In addition, he is working on testing new technology to improve the donor organ supply.

Dr. Torres earned his medical degree at Cornell University Medical College in New York. He completed his internship and residency at UT Southwestern and a fellowship in pulmonary disease, critical care medicine, lung transplantation, and lung volume reduction at the University of Colorado Health Sciences Center in Denver.

*This physician is being compensated by Bayer for clinical expertise and contributions to this site.

CTEPH.com

Healthcare Professionals

Patients and Caregivers

If you would prefer to visit your local website, please select your country: